February 9, 2023: Dr. Diana Zuckerman of NCHR urges the FDA Oncology Advisory Committee to require randomized trials of Jemperli for rectal cancer instead of single arm trials, so that patients and physicians can make informed decisions about the best treatment.
Read More »Author: Caroline Bradford
NCHR Comments on USPTO-FDA Collaboration and Engagement
February 6, 2023: NCHR’s public comments strongly support FDA’s decision to prioritize USPTO-FDA collaboration. Access to generic drugs and biosimilars is critically important and abuse of the patent system remains a major barrier. We are hopeful that meaningful collaboration between the FDA and the USPTO will result in substantial improvements.
Read More »NCHR Comments on HHS Proposed Rule Regarding Confidentiality of Substance Use Disorder (SUD) Patient Records
January 31, 2023: NCHR’s public comment criticizes the HHS plan to align privacy standards with HIPAA instead of Part 2. We are concerned that loss of privacy for patients with substance abuse disorder (SUD) could stigmatize them or discourage them from seeking treatment.
Read More »NCHR Comments on the CDC proposed new Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children
January 27, 2023: Hepatitis C infections have dramatically increased among pregnant women, which exposes babies during birth. National Center for Health Research supports CDC’s recommendations for HCV testing of all infants and children born to pregnant mothers with confirmed or probable HCV.
Read More »NCHR Statement on Transparency of Children’s Clinical Trials
January 24, 2023: A new report finds that 3,627 American children participated in clinical trials whose results remain hidden. This is not ‘only’ unethical – it’s illegal.
Read More »